Fulcrum Therapeutics (FULC) Expected to Announce Earnings on Monday

Fulcrum Therapeutics (NASDAQ:FULC) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.29) per share for the quarter.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. On average, analysts expect Fulcrum Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulcrum Therapeutics Stock Down 0.7 %

Shares of FULC stock opened at $5.37 on Friday. The firm’s 50 day moving average price is $3.38 and its two-hundred day moving average price is $3.70. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $10.13. The stock has a market cap of $289.87 million, a price-to-earnings ratio of -17.32 and a beta of 2.29.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.63.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.